Spectral Med Inc is seeing a significant rise in its stock price, which reflects positive sentiment from investors.
Today, Spectral Med Inc (EDT.TO) gained 3.51%, closing at CA$1.18. This increase is encouraging for investors looking for growth in the biotech sector.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$346.39M
52W high
$1.65
52W low
$1.03
1W change
+2.61%
Beta
0.18
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 166.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+166.9% Upside
Current Price
C$1.18
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
38.1%
Annualized
90-Day Vol
31.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.11 | C$0.97 – C$1.27 |
| 60 trading days | C$1.05 | C$0.87 – C$1.26 |
| 90 trading days | C$0.99 | C$0.79 – C$1.24 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent rise in Spectral Med's stock price may show growing confidence among investors, likely driven by the company's progress in regulatory processes and clinical trials.
Spectral Med Inc's stock up by 3.51%
The company's market cap is now CA$346.4 million, highlighting its expanding presence in the medical technology industry.
Bull case
With the FDA's acceptance of the Premarket Approval application for PMX, Spectral Med is setting itself up for future growth. If the company successfully commercializes its endotoxin removal therapy, it could greatly enhance its market presence and revenue potential.
Bear case
Despite today's gains, investors should stay cautious. The biotech sector can be unpredictable, and any delays or setbacks in regulatory approvals could hurt stock performance.
Market Performance Overview
Advertisement
Spectral Med Inc's stock is gaining traction in the market, reflecting a 3.51% increase today. This rise is noteworthy given the company's recent activities and advancements in its product pipeline.
Key Developments Driving Growth
The acceptance of the FDA's PMA application for PMX is a major milestone for Spectral Med. This development could open doors for future revenue streams and boost investor confidence.
Looking Ahead
Investors should keep a close eye on Spectral Med's progress. While today's gains are promising, the company's future will depend on successfully navigating regulatory challenges and market competition. For more information, visit Spectral Med Inc stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
